Intensity Therapeutics, Inc. INTS 深 沪
已收盘 09-26 16:00:00 美东时间
0.2426
-0.005
-2.18%
华盛通- 最 高0.25
- 今 开0.25
- 成交量 106.34万股
- 最 低 0.2301
- 昨 收 0.248
- 总市值 1190.09万
- 52周最高 3.9999
- 市盈率 静 --
- 换手率 2.17%
- 52周最低 0.1853
- 委 比 99.74%
- 总股本 4905.55万
- 历史最高 11.44
- 量 比 0.69
- 振 幅 8.02%
- 历史最低 0.1853
- 每 手 1
- 风险率 1.23%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多Intensity Therapeutics Pauses Enrollment in INVINCIBLE-4 Study
An update from Intensity Therapeutics, Inc. ( ($INTS) ) is now available. On Se...
09-11 04:38
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
Gainers Cuprina Holdings (Cayman) (NASDAQ:CUPR) shares increased by 239.0% to ...
09-10 20:11
Intensity Therapeutics Reports Early Radiological And Pathological Results With INT230 6 Demonstrating High Drug Absorption Tumor Necrosis And Evidence Of Immune Activation
A pathological complete response ("pCR") has been observed in the first patient evaluated in Cohort A, where each patient receives two doses of INT230-6 eight days apart, followed by the standard of care
09-10 19:49
Benchmark Maintains Speculative Buy on Intensity Therapeutics, Lowers Price Target to $1.5
Benchmark analyst Robert Wasserman maintains Intensity Therapeutics (NASDAQ:INTS) with a Speculative Buy and lowers the price target from $4 to $1.5.
08-20 20:59
Intensity Therapeutics Reports Reduced Losses and Clinical Progress
Intensity Therapeutics, Inc. ( ($INTS) ) has released its Q2 earnings. Here is ...
08-14 12:23
美股机会日报丨贝森特称九月或降息50个基点；中国资产爆发！网易盘前涨超5%，阿里巴巴盘前涨超3%
贝森特称九月或降息50个基点；中国资产爆发！网易盘前涨超5%，阿里巴巴盘前涨超3%；马斯克：特斯拉Robotaxi9月将向公众开放>>
08-13 21:03
美股大行评级 | 潜在涨幅921.1%！Intensity Therapeutics获Brookline Capital升级至"买入"，目标价上调至3美元
今日重点评级关注：Brookline Capital：上调Intensity Therapeutics评级至"买入"，目标价3美元；Chardan Capital：维持Taysha Gene Therapies"买入"评级，目标价从9美元升至10美元
08-13 09:10
Intensity Therapeutics Amends Bylaws for Quorum Change
The latest update is out from Intensity Therapeutics, Inc. ( ($INTS) ). On Augu...
08-13 05:15
Brookline Capital Upgrades Intensity Therapeutics to Buy, Announces $3 Price Target
Brookline Capital analyst Kumaraguru Raja upgrades Intensity Therapeutics (NASDAQ:INTS) from Hold to Buy and announces $3 price target.
08-13 05:06
Intensity Therapeutics regains compliance with Nasdaq requirement
Intensity Therapeutics (NASDAQ:INTS) said on Tuesday that the biotechnology company has regained compliance with Nasdaq's minimum stockholders' equity requirement. On August 7, the company filed its q...
08-12 21:13
